Cytokinetics Company Profile (NASDAQ:CYTK)

About Cytokinetics

Cytokinetics logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTK
  • CUSIP:
Key Metrics:
  • Previous Close: $11.25
  • 50 Day Moving Average: $11.52
  • 200 Day Moving Average: $10.77
  • 52-Week Range: $40,581,000.00 - $6.00
  • Trailing P/E Ratio: 28.85
  • Foreward P/E Ratio: -6.47
  • P/E Growth: -0.37
  • Market Cap: $456.54M
  • Outstanding Shares: 40,581,000
  • Beta: 1.79
Profitability:
  • Net Margins: -1.70%
  • Return on Equity: -2.17%
  • Return on Assets: -1.14%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 5.32%
  • Quick Ratio: 5.05%
Additional Links:
Companies Related to Cytokinetics:

Analyst Ratings

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $18.88 (67.78% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Cantor FitzgeraldReiterated RatingOverweight$21.00View Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00View Rating Details
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$22.00View Rating Details
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00View Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/31/2016Cowen and CompanyReiterated RatingOutperform$16.00View Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
7/28/2016Q2($0.28)($0.29)ViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)ViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
4/30/2015Q1($0.12)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)ViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
Current Year EPS Consensus Estimate: $-2.03 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.33)($0.33)($0.33)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.42)($0.42)($0.42)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 66.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.88View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK) Following 4Q16 Results - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - February 19 at 11:08 AM
News IconPlenty of Catalysts Ahead for Cytokinetics (CYTK) - Economic Calendar (NASDAQ:CYTK)
www.economiccalendar.com - February 19 at 11:08 AM
News IconEquity Watch: Looking at Shares of Cytokinetics Incorporated (CYTK) - Baldwin Journal (NASDAQ:CYTK)
baldwinjournal.com - February 18 at 8:09 AM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Incorporated (NASDAQ:CYTK) (NASDAQ:CYTK)
marketexclusive.com - February 17 at 8:03 PM
us.rd.yahoo.com logoEdited Transcript of CYTK earnings conference call or presentation 16-Feb-17 9:30pm GMT (NASDAQ:CYTK)
us.rd.yahoo.com - February 17 at 8:03 PM
4-traders.com logoCytokinetics : beats 4Q profit forecasts (NASDAQ:CYTK)
www.4-traders.com - February 16 at 7:02 PM
4-traders.com logoCytokinetics : beats 4Q profit forecasts (NASDAQ:CYTK)
www.4-traders.com - February 16 at 7:02 PM
us.rd.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD) (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
us.rd.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD) (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
us.rd.yahoo.com logoCytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
us.rd.yahoo.com logoCytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
biz.yahoo.com logoCytokinetics Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
biz.yahoo.com logoCytokinetics Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CYTK)
us.rd.yahoo.com - February 16 at 7:02 PM
sg.finance.yahoo.com logoCytokinetics beats 4Q profit forecasts (NASDAQ:CYTK)
sg.finance.yahoo.com - February 16 at 7:02 PM
News IconCytokinetics, Incorporated (CYTK) investors have generally offloaded the stock after recent earnings reports - Post Analyst (NASDAQ:CYTK)
postanalyst.com - February 16 at 2:00 PM
biz.yahoo.com logoQ4 2016 Cytokinetics Inc Earnings Release - 4:00 pm ET (NASDAQ:CYTK)
biz.yahoo.com - February 16 at 2:00 PM
News IconWhat is the Street Saying About Cytokinetics, Incorporated ... - Aiken Advocate (NASDAQ:CYTK)
aikenadvocate.com - February 15 at 3:33 AM
capitalcube.com logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : February 7, 2017 (NASDAQ:CYTK)
www.capitalcube.com - February 7 at 5:46 PM
capitalcube.com logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : February 7, 2017 (NASDAQ:CYTK)
www.capitalcube.com - February 7 at 5:46 PM
us.rd.yahoo.com logoCytokinetics upgraded by Needham (NASDAQ:CYTK)
us.rd.yahoo.com - February 6 at 4:41 PM
thestreet.com logoBiotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird (NASDAQ:CYTK)
www.thestreet.com - February 6 at 4:41 PM
News IconInteresting CYTK Put And Call Options For August 18th (NASDAQ:CYTK)
www.stockoptionschannel.com - February 3 at 4:58 PM
finance.yahoo.com logoCytokinetics to Announce Fourth Quarter Results on February 16, 2017 (NASDAQ:CYTK)
finance.yahoo.com - February 3 at 4:58 PM
News Icon$100M positions Cytokinetics well re Amgen with omecamtiv (NASDAQ:CYTK)
www.bioworld.com - February 2 at 10:04 PM
bizjournals.com logoPeninsula biotech gets $100M royalty deal for drug that won't hit market for at least 4 years (NASDAQ:CYTK)
www.bizjournals.com - February 2 at 5:03 PM
streetinsider.com logoCytokinetics (CYTK) to Sell Royalty Pharma Portion of Potential Royalty from Omecamtiv Mecarbil (NASDAQ:CYTK)
www.streetinsider.com - February 2 at 5:03 PM
investopedia.com logoCytokinetics Sells Royalties on Heart Drugs (CYTK) (NASDAQ:CYTK)
www.investopedia.com - February 2 at 5:03 PM
us.rd.yahoo.com logoCytokinetics and Royalty Pharma Announce $100 Million Transaction for Omecamtiv Mecarbil (NASDAQ:CYTK)
us.rd.yahoo.com - February 2 at 5:03 PM
marketwatch.com logoCytokinetics will sell percentage of royalties on heart failure drug for $90 million (NASDAQ:CYTK)
us.rd.yahoo.com - February 2 at 5:03 PM
investopedia.com logoCytokinetics Inks $100M Royalty Sharing Deal (NASDAQ:CYTK)
www.investopedia.com - February 2 at 5:03 PM
News IconChecking the Metrics on Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - The Tribune (NASDAQ:CYTK)
lakecitytribune.com - January 27 at 6:07 PM
News IconEarnings in Full Force, Analysts Take Aim at Cytokinetics, Incorporated (NASDAQ:CYTK) - Wall Street Beacon (NASDAQ:CYTK)
wsbeacon.com - January 26 at 5:52 PM
News IconSetting the Table For Earnings, Stock In Focus: Cytokinetics, Incorporated (NASDAQ:CYTK) - Aiken Advocate (NASDAQ:CYTK)
aikenadvocate.com - January 26 at 5:52 PM
News IconWhat are Research Firms Saying About Cytokinetics, Incorporated (NASDAQ:CYTK)? - Aiken Advocate (NASDAQ:CYTK)
aikenadvocate.com - January 25 at 3:20 AM
News IconMonitoring Relative Strength Index Values for Cytokinetics Incorporated (CYTK) - Sherwood Daily (NASDAQ:CYTK)
sherwooddaily.com - January 20 at 5:50 PM
capitalcube.com logoCytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : January 19, 2017 (NASDAQ:CYTK)
www.capitalcube.com - January 19 at 5:56 PM
News IconStock Review: ADX, MA, RSI Numbers in View for Cytokinetics Incorporated (CYTK) - Sherwood Daily (NASDAQ:CYTK)
sherwooddaily.com - January 18 at 5:00 PM
capitalcube.com logoCytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : January 18, 2017 (NASDAQ:CYTK)
www.capitalcube.com - January 18 at 5:00 PM
News IconStock Momentum Skidding to a Halt For Cytokinetics, Incorporated (NASDAQ:CYTK) - Wall Street Beacon (NASDAQ:CYTK)
wsbeacon.com - January 17 at 5:30 PM
News IconTechnical Study: Following Indicators for Cytokinetics Incorporated (CYTK) - Springdale Times (NASDAQ:CYTK)
springdaletimes.com - January 17 at 8:33 AM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Cytokinetics, Incorporated (NASDAQ:CYTK) - Prospect Journal (NASDAQ:CYTK)
prospectjournal.com - January 17 at 8:33 AM
News IconCytokinetics Inc CYTK Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CYTK)
www.bioportfolio.com - January 11 at 10:09 PM
live-pr.com logoCytokinetics, Inc. (CYTK) - Financial and Strategic SWOT Analysis Review - New Study Released (NASDAQ:CYTK)
www.live-pr.com - January 11 at 10:09 PM
News IconEqis Capital Management Lowers stake in Cytokinetics (CYTK) - Highland Mirror (NASDAQ:CYTK)
www.highlandmirror.com - January 11 at 5:07 PM
News Icon3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock - Yahoo Sports (NASDAQ:CYTK)
sports.yahoo.com - December 31 at 9:42 PM
finance.yahoo.com logo3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock (NASDAQ:CYTK)
finance.yahoo.com - December 30 at 5:01 PM
finance.yahoo.com logoCytokinetics (CYTK): Strong Industry, Solid Earnings Estimate Revisions (NASDAQ:CYTK)
finance.yahoo.com - December 22 at 4:49 PM
globenewswire.com logoCytokinetics Added to Nasdaq Biotechnology Index Nasdaq:CYTK - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - December 16 at 10:08 PM

Social

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2017?

8 brokers have issued 12-month price targets for Cytokinetics' shares. Their predictions range from $14.00 to $24.00. On average, they expect Cytokinetics' share price to reach $18.88 in the next year.

When will Cytokinetics announce their earnings?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

  • Cantor Fitzgerald analysts commented, "We rate CYTK Overweight and maintain our $21 price target. Cytokinetics has three late-stage programs with quality partners that should begin to read data out in the next year. The company is targeting substantial unmet medical needs and has been methodically pursuing clinical development for its candidates. We think the major overhangs have receded from the shares and that, with near-term data on the horizon, the shares have opportunity for valuation expansion." (2/17/2017)
  • FBR & Co analysts commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program (omecamtiv mecarbil, or OM) and important milestones in its skeletal muscle program (tirasemtiv and CK-2127107), which we think will continue to emerge in value in 2017. One highlight was the initiation of the GALACTIC-HF Phase III outcomes trial with OM by its partner Amgen. Another 4Q highlight was enrollment of the first patient in the open-label VIGOR-ALS trial with tirasemtiv, designed to assess the safety of tirasemtiv, which would be directed for long-term daily use in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). We think CYTK's valuation is disconnected from the value of the more than $1B in milestone payments that CYTK could realize from its partners. Therefore, we reiterate our Outperform rating." (2/17/2017)
  • Piper Jaffray Companies analysts commented, "On Thursday AMC Cytokinetics reported 4Q16 financial results, including $33M in revenues and $156M in YE16 cash. Following the recent Royalty Pharma transaction for omecamtiv , Cytokinetics' balance sheet should now fund pipeline progress to 2H18. With this transaction complete, we like the set-up into higher-risk/higher-reward endeavors during 2017. In this category, we include exploratory data for second-gen '107 in SMA and COPD during 2H17, as well as potentially pivotal data for tirasemtiv in ALS during 4Q17. Positive results here could enhance conviction for the troponin activation platform, and point to the company's first commercial-stage product in ALS. In advance of this potentially transformative clinical progress in the next ~12 months, we reiterate OW." (2/17/2017)
  • According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (2/7/2017)

  • Needham & Company LLC analysts commented, "The Phase III VITALITY-ALS study of tirasemtiv in amyotrophic lateral sclerosis (ALS) is expected to read out by year end. The Phase IIb study missed its primary endpoint, leading to low investor expectations of the outcome for Phase III. However, this well powered (n=711) trial hit on the pre-specified secondary endpoint of slow vital capacity (SVC) with high statistical significance (p=0.0006) and SVC is the primary endpoint in VITALITY. Cytokinetics owns US and European rights to tirasemtiv and intends to commercialize the drug on its own. We forecast >$300M in 2022 US sales. Following a recent royalty financing, we estimate Cytokinetics holds >$230M in pro forma cash, which we believe is more than adequate to launch tirasemtiv." (2/6/2017)

Who owns Cytokinetics stock?

Cytokinetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (12.83%), Lansdowne Partners UK LLP (5.73%), State Street Corp (2.22%), Palo Alto Investors LLC (0.31%), EcoR1 Capital LLC (0.14%) and Keybank National Association OH (0.10%). Company insiders that own Cytokinetics stock include Andrew A Wolff, Fady Ibraham Malik and L Patrick Gage.

Who sold Cytokinetics stock? Who is selling Cytokinetics stock?

Cytokinetics' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, State Street Corp, Two Sigma Investments LP, Tudor Investment Corp Et Al, AQR Capital Management LLC and Keybank National Association OH.

Who bought Cytokinetics stock? Who is buying Cytokinetics stock?

Cytokinetics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, A.R.T. Advisors LLC, Bayesian Capital Management LP, Dynamic Technology Lab Private Ltd and Fortaleza Asset Management Inc..

How do I buy Cytokinetics stock?

Shares of Cytokinetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytokinetics stock cost?

One share of Cytokinetics stock can currently be purchased for approximately $11.25.

Cytokinetics (NASDAQ:CYTK) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Earnings History Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Dividend History Chart

Dividend Payments by Quarter for Cytokinetics (NASDAQ:CYTK)

Last Updated on 2/20/2017 by MarketBeat.com Staff